Neurologic Manifestations of Long COVID Differ Based on Acute COVID-19 Severity
Ann Neurol 94:146-159, Giraldo,G.S.P.,et al, 2023
Progressive Multifocal Leukoencephalopathy in a Patient with Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy
JAMA Neurol 78:736-740, Patel,A.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Varicella-Zoster Virus Infections in Patients Treated with Fingolimod
JAMA Neurol 72:31-39,10, Arvin, A.M.,et al, 2015
Varicella-Zoster Virus Acute Myelitis in a Patient with MS Treated with Natalizumab
Neurol 80:1812-1813, Yeung, J.,et al, 2013
Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009
Tick-Borne Encephalitis
Lancet 371:1861-1871, Lindquist,L. &Vapalahti,O., 2008
Multiple Sclerosis After Infectious Mononucleosis
Arch Neurol 64:72-75, Nielsen,T.R.,et al, 2007
Temporal Relationship Between Elevation of Epstein-Barr Virus Antibody Titers and Initial Onset of Neurological Symptoms in Multiple Sclerosis
JAMA 293:2496-2500, Levin,L.I.,et al, 2005
Epstein-Barr Virus in Pediatric Multiple Sclerosis
JAMA 291:1875-1879, Alotaibi,S.,et al, 2004
Multiple Sclerosis and Epstein-Barr Virus
JAMA 289:1533-1536, Levin,L.I.,et al, 2003
Bacterial Infection as a Cause of Multiple Sclerosis
Lancet 360:352-353, Wolfson,C. &Talbot,P., 2002
Epstein-Barr Virus Antibodies and Risk of Multiple Sclerosis
JAMA 286:3083-3088,3127, Ascherio,A.,et al, 2001
Multiple Sclerosis and Antecedent Infections
Neurol 54:2307-2310, Marrie,R.A.,et al, 2000
Lack of JC Viral Sequences in Multiple Sclerosis Brain Tissue by Polymerase Chain Reaction
Ann Neurol 32:829-831, Buckle,G.J.,et al, 1992
Implications of Progressive Multifocal Leukoencephalopathy and JC Virus for the Etiology of MS
Acta Neurol Scand 83:20-23, Stoner,G.L., 1991
Retroviruses and Multiple Sclerosis. I. Analysis of Seroreactivity by Western Blot and Radioimmune Assay
Neurol 40:1251-1253, Weinshenker,B.G.,et al, 1990
Retroviruses & Multiple Sclerosis. II. Failure of Gene Amplification Techniques to Detect Viral Sequences
Neurol 40:1254-1258, Dekaban,G.A.&Rice,G.P.A., 1990
Recovery of Paramyxovirus from the Jejunum of Patients with Multiple Sclerosis
Lancet p. 117, May 28977., Prasad,I.,et al, 1977
Fusion of Cultured Multiple-Sclerosis Brain Cells with Indicator Cells:Isolate of Parainfluenza-Type Virus
Lancet 7766, 1972, July., Meulen,V.,et al, 1972
Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19
NEJM 382:e38, Zhang, Y.,et al, 2020
Scoping Review of Prevalence of Neurologic Comorbidities in Patients Hospitalized for COVID-19
Neurol 95:77-84, Herman, C.,et al, 2020
Diagnostic Challenges and Clinical Characteristics of Hepatitis E Virus-Associated Guillain-Barre Syndrome
JAMA Neurol 74:26-33, Stevens, O.,et al, 2017
Enterovirus Vaccines for an Emerging Cause of Brain-Stem Encephalitis
NEJM 370:792-794, McMinn, P.C., 2014
Subacute Sclerosing Panencephalitis
www.MedLink.com, February, Auwaeter,P.G.&Johnson,R.T., 2013
Guillain-Barre Syndrome
NEJM 366:2294-2304, Yuki, N. & Hartung, H.P., 2012
Multiple Sclerosis Rebound Following Herpes Zoster Infection and Suspension of Fingolimod
Neurol 79:2006-2007,1942, Gross, C.M.,et al, 2012
Pediatric Neurological Complications of 2009 Pandemic Influenza A (H1N1)
Arch Neurol 68:455-462, Kedia, S.,et al, 2011
Differential Features of Carotid and Vertebral Artery Dissections
Neurol 77:1174-1181, Debette, S.,et al, 2011
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
NEJM 362:402-415, 456, Cohen,J.A.,et al, 2010
JC Virus Infection of the Brain
AJNR 31:1564-1576, Bag,A.K.,et al, 2010
AIDS-Related Lymphomas: Epidemiology, Risk Factors, and Pathobiology
UpToDate, Sept, Kaplan, L.D.,et al, 2010
Triple and Quadruple Spontaneous Cervical Artery Dissection: Presenting Characteristics and Long-Term Outcome
JNNP 80:171-174,130, Arnold,M.,et al, 2009
FDA Public Health advisory-Suspended Marketing of Tysabri (natalizumab)
www.fda.gov/cder/drug/advisory/natalizumab.htm.,(Feb 28), US Food and Drug Admin., 2005
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
NEJM 353:369-374,414,432, Kleinschemidt-DeMasters,B.K. &Tyler,K.L., 2005
Acute Disseminated Encephalomyelitis
Arch Neurol 62:1673-1680, Menge,T.,et al, 2005
Guillain-Barre Syndrome
Lancet 366:1653-1666, Hughes,R.C. &Comblath,D.R., 2005
Chickenpox and Stroke in Childhood
Stroke 32:1257-1262, Askalan,R.,et al, 2001
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Neurologic Manifestations of AIDS
Medicine 66:407-437, McArthur,J.C., 1987
Three Territory Sign in COVID-19
Acta Neurol Belg doi.10.1007/s13760-021-01842-8, Bhatele, P.,et al, 2022
Acute Flaccid Myelitis: Cause, Diagnosis, and Management
Lancet 394:334-397, Murphy, O.C.,et al, 2021
Neurologic Complications of Coronavirus Infections
Neurol 94:809-810, Nath, A., 2020
The Spectrum of Neurologic Disease in the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic Infection
JAMA Neurol 77:679-680, Pleasure, S.J.,et al, 2020
Clinicopathologic Conference, Cerebrovascular Accident Probably Related to SARS-CoV2 Infection
NEJM 383:764-773, Case 26-2020, 2020
Fat Embolism Syndrome in Sickle Cell Disease
J Clin Med 9:1-12, Tsitsikas, D.A.,et al, 2020
Acute Encephalitis in Immunocompetent Adults
Lancet 393:702-716, Venkatesan, A.,et al, 2019
Neuroimaging Findings of Zika Virus-Associated Neurologic Complications in Adults
AJNR 39:1967-1974, Hygino da Cruz, L.C.,et al, 2018
Viral Hepatitis and Parkinson Disease
Neurol 88:1630-1633, Pakpoor, J.,et al, 2017